Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 17:14:1102297.
doi: 10.3389/fneur.2023.1102297. eCollection 2023.

Short-term effects of intravenous batroxobin in treatment of sudden sensorineural hearing loss: a propensity score-matched study

Mengzhu Jiang #  1   2 , Huping Huang #  1   2 , Lingyun Mei  1   2   3 , Chufeng He  1   2   3 , Xinzhang Cai  1   2   3 , Lu Jiang  1   2   3 , Hong Wu  1   2   3 , Xin Wang  1   2 , Xuewen Wu  1   2   3
Affiliations

Short-term effects of intravenous batroxobin in treatment of sudden sensorineural hearing loss: a propensity score-matched study

Mengzhu Jiang et al. Front Neurol. .

Abstract

Background: Sudden sensorineural hearing loss (SSNHL) can cause great panic in patients. Whether it is advantageous to add intravenous batroxobin in the treatment of SSNHL remains to be determined. This study aimed to compare the short-term efficacy of therapy combined with intravenous batroxobin and that without intravenous batroxobin in SSNHL patients.

Methods: This retrospective study harvested the data of SSNHL patients hospitalized in our department from January 2008 to April 2021. The hearing levels on the admitted day (before treatment) and the discharge day were considered pre-treatment hearing and post-treatment hearing, respectively. The hearing gain was the difference value of pre-treatment hearing and post-treatment hearing. We used Siegel's criteria and the Chinese Medical Association of Otolaryngology (CMAO) criteria to evaluate hearing recovery. The complete recovery rate, overall effective rate, and hearing gain at each frequency were considered outcomes. Propensity score matching (PSM) was conducted to balance the baseline characteristics between the batroxobin group and the non-batroxobin group. Sensitivity analysis was carried out in flat-type and total-deafness SSNHL patients.

Results: During the study period, 657 patients with SSNHL were admitted to our department. Among them, a total of 274 patients met the enrolled criteria of our study. After PSM, 162 patients (81 in each group) were included in the analysis. Once the hospitalized treatment was completed, the patients would be discharged the next day. Logistic regression analysis of the propensity score-matched cohort indicated that both the complete recovery rates [Siegel's criteria, OR: 0.734, 95% CI: 0.368-1.466, p = 0.381; CMAO criteria, OR: 0.879, 95% CI: 0.435-1.777, p = 0.720] and the overall effective rates [Siegel's criteria and CMAO criteria, OR: 0.741, 95% CI: 0.399-1.378, p = 0.344] were not significantly different between the two treatment groups. Sensitivity analysis has shown similar results. For flat-type and total-deafness SSNHL patients, no significant difference was found in post-treatment hearing gain at each frequency between the two groups after PSM.

Conclusion: There was no significant difference in short-term hearing outcomes between treatment with batroxobin and treatment without batroxobin in SSNHL patients by Siegel's and CMAO criteria after PSM. Future studies for better therapy regimens of SSNHL are still needed.

Keywords: intravenous batroxobin; propensity score matching; short-term effects; sudden sensorineural hearing loss; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart depicting patient selection.
Figure 2
Figure 2
Comparison of pre-treatment hearing and hearing gains between the batroxobin group and the non-batroxobin group in the sensitivity analysis. (A) Pre-treatment hearing level of batroxobin group and non-batroxobin group before PSM. (B) Hearing gains of batroxobin group and non-batroxobin group before PSM. (C) Pre-treatment hearing level of batroxobin group and non-batroxobin group after PSM. (D) Hearing gains of batroxobin group and non-batroxobin group after PSM. The black bar represents the batroxobin group and the gray bar represents the non-batroxobin group, * stands for a p-value of <0.05.
See this image and copyright information in PMC

References

    1. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, et al. . Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg. (2019) 161:S1–45. 10.1177/0194599819859885 - DOI - PubMed
    1. Michel O, Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Die aktuell gefasste Leitlinie “Hörsturz” (Akuter idiopathischer sensorineuraler Hörverlust) [The revised version of the german guidelines “sudden idiopathic sensorineural hearing loss”]. Laryngorhinootologie. (2011) 90:290–3. German. 10.1055/s-0031-1273721 - DOI - PubMed
    1. Chau JK, Lin JR, Atashband S, Irvine RA, Westerberg BD. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope. (2010) 120:1011–21. 10.1002/lary.20873 - DOI - PubMed
    1. Koçak HE, Filiz Acipayam AS, Acipayam H, Çakil Erdogan B, Alakhras WME, Kiral MN, et al. . Microvascular dysfunction affects the development and prognosis of sudden idiopathic hearing loss. Clin Otolaryngol. (2017) 42:602–7. 10.1111/coa.12780 - DOI - PubMed
    1. Jung SY, Shim HS, Hah YM, Kim SH, Yeo SG. Association of metabolic syndrome with sudden sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg. (2018) 144:308–14. 10.1001/jamaoto.2017.3144 - DOI - PMC - PubMed